Aldosterone Sex- and Cycle-Related Differences: Normal Range, Optimal Levels, and What Your Labs Mean

What Is Aldosterone and Why Does It Matter?

Aldosterone is the principal mineralocorticoid produced by the zona glomerulosa of the adrenal cortex. Its job is to retain sodium and excrete potassium across the distal nephron, which drives extracellular fluid volume and blood pressure upward. When it rises inappropriately, the result is resistant hypertension, hypokalemia, left ventricular hypertrophy, and accelerated cardiovascular remodeling that exceeds what blood-pressure numbers alone would predict. [1]

The Endocrine Society's 2016 Clinical Practice Guideline on primary aldosteronism states: "Cardiovascular complications in primary aldosteronism exceed those expected from hypertension alone, including higher rates of stroke, myocardial infarction, and atrial fibrillation." [2]

The Renin-Angiotensin-Aldosterone Axis

Aldosterone does not act in isolation. Renin, released from the juxtaglomerular cells of the kidney, cleaves angiotensinogen to angiotensin I, which converts to angiotensin II and then stimulates aldosterone secretion. Low sodium, low blood pressure, upright posture, and volume depletion all push renin and aldosterone upward together. That context is essential for interpreting any single aldosterone measurement.

Why Single Values Mislead

A fasting, supine aldosterone of 6 ng/dL in a man on a normal-sodium diet is unremarkable. The same 6 ng/dL in a woman who drew blood standing after a low-sodium breakfast in her mid-luteal phase may be relatively suppressed. Without draw conditions, cycle phase, and concurrent plasma renin activity (PRA) or direct renin concentration (DRC), no aldosterone number is fully interpretable.

Aldosterone Normal Range vs. Optimal Range

Conventional Laboratory Reference Intervals

Most commercial laboratories in the United States report aldosterone reference intervals of roughly 2 to 9 ng/dL for supine, fasted, sodium-replete adults. The range widens to 3 to 16 ng/dL or higher for ambulatory (seated or standing) samples because posture stimulates renin release by 2 to 4 fold. [3]

These ranges are not tight. They were derived from small reference populations and do not always separate by sex, cycle phase, age, or dietary sodium intake. A result reported as "within normal limits" can still reflect subtle autonomous secretion when renin is appropriately suppressed.

The Aldosterone-to-Renin Ratio Is the Operative Screen

Because absolute aldosterone alone is insufficient, the aldosterone-to-renin ratio (ARR) is the primary screening tool recommended by the Endocrine Society. Using plasma renin activity (PRA) as the denominator, an ARR above 30 (ng/dL per ng/mL/h) with an aldosterone above 15 ng/dL has sensitivity approaching 90% for primary aldosteronism in hypertensive cohorts. [2]

Longevity-Medicine and Functional Perspectives

Functional and longevity medicine practitioners often target an aldosterone of 4 to 9 ng/dL with PRA of 1 to 3 ng/mL/h. This places the ARR clearly below 10, supports adequate potassium retention without overt volume expansion, and avoids the chronic low-grade cardiac and renal stress that may accompany persistently elevated aldosterone even within the "normal" range. No large randomized trial has prospectively validated this tighter target, so the recommendation is expert consensus rather than level-A evidence.

The practical framework at HealthRX is: report absolute aldosterone, PRA or DRC, calculated ARR, draw posture, time of day, dietary sodium context, and cycle phase together. Treating any one value in isolation misses the picture.

Sex-Based Differences in Aldosterone

Baseline Differences Between Men and Women

Men and women show overlapping but distinct aldosterone distributions at baseline. A 2021 analysis published in the Journal of the Endocrine Society examining 3,112 normotensive adults found median aldosterone was 7.1 ng/dL in women vs. 5.8 ng/dL in men when samples were drawn in the follicular phase of the menstrual cycle (day 3 to 8), matched for posture and sodium intake (P<0.001). [4]

The difference is modest in absolute terms but clinically meaningful when interpreting borderline ARR values, because an ARR of 25 in a woman in her follicular phase may reflect physiologic variation rather than autonomous secretion.

Estrogen and the Renin-Angiotensin-Aldosterone System

Estrogen stimulates hepatic production of angiotensinogen, the renin substrate. Higher angiotensinogen means more substrate available for renin to cleave. The net effect is a higher circulating renin and, secondarily, higher aldosterone. This mechanism explains why women on combined oral contraceptives containing ethinyl estradiol can show aldosterone values 20 to 40% above their pill-free baseline. [5]

Women starting estrogen therapy for menopause management may see similar increases. These are not pathological elevations but they can create false-positive ARR screens if the estrogen context is not documented at the time of the draw.

Progesterone as a Mineralocorticoid Antagonist

Progesterone and its metabolites, especially 17-hydroxyprogesterone, bind the mineralocorticoid receptor with moderate affinity but act as competitive antagonists rather than agonists. The luteal phase, when progesterone peaks to 5 to 20 ng/mL, therefore triggers a compensatory rise in aldosterone: the kidney senses relative mineralocorticoid receptor blockade and the zona glomerulosa responds by secreting more aldosterone to maintain sodium balance. [6]

This is the single most important physiological fact for interpreting female aldosterone labs. A woman in her luteal phase can show aldosterone values 1.5 to 2.5 times her follicular-phase baseline without any adrenal pathology whatsoever.

Cycle-Phase-Specific Reference Values

Follicular Phase (Days 1 to 13)

Aldosterone during the follicular phase, when both estrogen and progesterone are relatively low, most closely resembles male reference ranges. Values of 2 to 9 ng/dL supine and 3 to 14 ng/dL seated are typical. If a definitive screening draw is needed in a premenopausal woman, the follicular phase (ideally days 3 to 8, after menses-related volume shifts have settled) provides the most stable baseline.

Periovulatory Phase (Days 12 to 16)

Estrogen surges acutely before ovulation. Aldosterone may rise transiently by 10 to 20% during this window, though the effect is smaller than the luteal rise. PRA typically rises proportionally, keeping the ARR relatively stable.

Luteal Phase (Days 15 to 28)

Progesterone peaks between days 19 to 22 of a 28-day cycle. Aldosterone typically peaks shortly after, driven by the compensatory mechanism described above. Published luteal-phase values in normotensive women range from 4 to 18 ng/dL in seated draws, with some studies reporting mean values of 10 to 12 ng/dL. [6, 7]

Screening for primary aldosteronism in a woman whose only abnormal value occurred during the luteal phase requires repeat testing in the follicular phase before any confirmatory workup is initiated.

Menstrual Phase (Days 1 to 5) and Cycle Transitions

The drop in progesterone and estrogen at the end of the luteal phase is accompanied by a mild natriuresis (the mechanism of premenstrual bloating resolution) and a transient fall in aldosterone. Some women show nadir aldosterone values in the first two days of menses. Repeat testing on day 1 to 2 of a cycle is not representative of a stable baseline.

Aldosterone in Pregnancy

Pregnancy produces the largest physiological aldosterone excursion seen in humans outside of adrenal disease. Plasma aldosterone rises progressively from the first trimester, driven by the 4 to 8 fold rise in renin that accompanies the progesterone-mediated vascular smooth muscle relaxation and the 30 to 50% increase in glomerular filtration rate. By the third trimester, aldosterone values of 15 to 100 ng/dL are normal and expected. [8]

Interpreting an aldosterone result from a pregnant patient using a non-pregnancy reference range is a clinical error. Any concern for aldosterone-producing adenoma during pregnancy requires specialist input and imaging protocols specifically designed for this setting, given the constraints on adrenal vein sampling and radiation exposure.

Aldosterone in Menopause and Hormone Therapy

Post-Menopausal Baseline

After menopause, the loss of cyclical progesterone removes the mineralocorticoid antagonist effect, and the loss of estrogen reduces angiotensinogen production. The net result is a modest fall in baseline aldosterone in many women, though individual variation is wide. Post-menopausal women generally show aldosterone values closer to male reference ranges, approximately 2 to 8 ng/dL fasting supine. [9]

Post-menopausal hypertension has a different aldosterone phenotype than pre-menopausal hypertension. A 2019 paper in Hypertension (N=14,709) found that post-menopausal women had a higher prevalence of aldosterone-associated hypertension than pre-menopausal women or age-matched men, possibly reflecting loss of the buffering effect of cyclical progesterone. [10]

Hormone Therapy Effects on Lab Interpretation

Oral estradiol raises angiotensinogen and can raise aldosterone by 15 to 30%. Transdermal estradiol at equivalent doses has a much smaller effect on angiotensinogen because it bypasses first-pass hepatic metabolism. This is clinically relevant: a woman on oral estradiol who is being screened for primary aldosteronism should ideally transition to transdermal estradiol for at least 4 weeks before the screening draw, or the result must be interpreted with that context noted. [5]

Progesterone supplementation (micronized progesterone, 100 to 200 mg nightly) can create the same compensatory aldosterone rise seen in the luteal phase. Synthetic progestins vary in their mineralocorticoid receptor affinity. Medroxyprogesterone acetate has weak mineralocorticoid agonist activity, while drospirenone has strong mineralocorticoid antagonist activity and can lower aldosterone or mask elevations.

Testosterone, Androgens, and Aldosterone

The data on testosterone and aldosterone are less consistent than the estrogen and progesterone literature.

Cross-sectional data suggest that higher free testosterone in men correlates weakly with lower aldosterone, possibly through direct inhibition of zona glomerulosa CYP11B2 (aldosterone synthase) activity. A mechanistic study in human adrenal cell lines published in the Journal of Clinical Endocrinology and Metabolism demonstrated testosterone reduced CYP11B2 expression by approximately 20% at physiologic concentrations. [11]

In women, androgen excess (as seen in polycystic ovary syndrome) is associated with higher aldosterone relative to renin, suggesting a shift toward relative autonomous secretion. The mechanism may involve adrenal co-secretion rather than a direct androgen effect on aldosterone synthesis. Screening PCOS patients with resistant or unexplained hypertension for primary aldosteronism is reasonable clinical practice.

Men undergoing testosterone replacement therapy (TRT) at physiologic doses (testosterone cypionate 100 to 200 mg/week or equivalent) generally show stable or slightly decreased aldosterone. Men using supraphysiologic doses, as in competitive bodybuilding, can develop significant fluid retention through aldosterone-independent androgen effects on renal tubules in addition to any aldosterone-mediated volume expansion.

How to Draw Aldosterone Correctly

Getting the draw right is as important as interpreting the result.

Pre-Draw Conditions

• Dietary sodium intake should be liberal (above 120 mEq/day) for at least 3 days before the draw. Low-sodium diets stimulate renin and raise aldosterone, potentially masking a suppressed renin that would otherwise flag autonomous secretion.
• The patient should be seated for at least 15 minutes before venipuncture. Some protocols require 2 hours of ambulatory activity followed by 15 minutes seated.
• Draw time should be between 08:00 and 10:00, as aldosterone follows a diurnal rhythm, peaking in the morning.
• For premenopausal women, document cycle day. Follicular-phase draws (days 3 to 8) are preferred for screening.

Medication Adjustments

Aldosterone antagonists (spironolactone, eplerenone) must be held for at least 4 weeks. Beta-blockers lower renin and can suppress the ARR, potentially masking primary aldosteronism by lowering the numerator proportionally less than the denominator. ACE inhibitors and ARBs raise renin and lower aldosterone; they can produce false-negative ARR values. The Endocrine Society guideline specifically lists medications that should be stopped before confirmatory testing when feasible. [2]

Units and Conversion

Many European laboratories report aldosterone in pmol/L. The conversion is 1 ng/dL = 27.7 pmol/L. An aldosterone of 250 pmol/L is approximately 9 ng/dL. Always confirm units before comparing results across different laboratories or published references.

When Aldosterone Is High: Differential and Next Steps

An elevated aldosterone with suppressed renin (low PRA) is the hallmark of primary aldosteronism. The Endocrine Society recommends confirmatory testing with either an oral sodium loading test, intravenous saline infusion test, fludrocortisone suppression test, or captopril challenge before proceeding to subtype differentiation. [2]

The prevalence of primary aldosteronism among hypertensive patients is approximately 6 to 10% in primary care cohorts and rises to 20% or higher in patients with treatment-resistant hypertension. [12] The condition is dramatically underdiagnosed: a 2020 analysis in the Annals of Internal Medicine estimated fewer than 2% of eligible hypertensive patients receive screening. [13]

An elevated aldosterone with elevated renin points toward secondary causes: renal artery stenosis, diuretic use, heart failure, cirrhosis, or a renin-secreting tumor.

When Aldosterone Is Low: Causes and Significance

Low aldosterone with elevated renin suggests adrenal insufficiency, including Addison disease or secondary adrenal insufficiency from pituitary or hypothalamic causes. Medications including NSAIDs, heparin, and calcineurin inhibitors can suppress aldosterone by inhibiting the renin-angiotensin pathway or directly suppressing the zona glomerulosa. Hypoaldosteronism causes sodium wasting, hyperkalemia, and hypotension.

Low aldosterone with low renin can reflect hyporeninaemic hypoaldosteronism, most commonly seen in type 4 renal tubular acidosis associated with diabetic nephropathy. These patients present with unexplained hyperkalemia despite preserved GFR.

Optimizing Aldosterone in Clinical Practice

For most healthy adults without hypertension or adrenal disease, maintaining adequate dietary sodium (not extreme restriction or excess), managing chronic psychological stress (which chronically activates the renin-angiotensin-aldosterone system via cortisol and sympathetic drive), and treating sleep apnea (a potent activator of aldosterone secretion) keeps aldosterone within a functional range without medication.

For patients with confirmed primary aldosteronism, treatment is either surgical (unilateral adrenalectomy for confirmed unilateral adenoma) or pharmacological (spironolactone 25 to 100 mg/day or eplerenone 50 to 200 mg/day for bilateral hyperplasia). Spironolactone reduces all-cause cardiovascular events in primary aldosteronism and normalizes left ventricular mass regression within 12 to 24 months of therapy. [14]

A morning fasting aldosterone below 4 ng/dL with PRA above 1 ng/mL/h and ARR clearly below 10 in a normotensive, normokalemic adult off confounding medications represents a reassuring adrenal profile that does not require further workup.